奥拉帕利致免疫性血小板减少症

Immune thrombocytopenia due to olaparib

1例69岁女性患者行卵巢癌细胞减灭术后接受白蛋白紫杉醇+卡铂方案化疗6个周期,此后予奥拉帕利300 mg口服、2次/d。服用奥拉帕利前血小板计数(PLT)151×109/L,用药第14天PLT为17×109/L,血小板相关免疫球蛋白检测结果阳性,考虑为奥拉帕利所致免疫性血小板减少症。患者未再服用奥拉帕利。先后给予血小板生成素、艾曲波帕、甲泼尼龙及输注血小板等治疗,但患者反复出现PLT回升和降低,最高为67×109/L,最低为4×109/L。

A 69‑year‑old female patient received olaparide 300 mg orally twice daily after 6 cycles of chemotherapy with albumin paclitaxel+carboplatin regimen after cytoreductive surgery for ovarian cancer.The platelet count(PLT)was 151×10^(9)/L before the olaparide treatment,and on the 14th day of medication,her platelet count(PLT)was 17×10^(9)/L and platelet‑associated immunoglobulin was positive.Immune thrombocytopenia due to olaparib was considered.The patient did not take the drug again.Thrombopoietin,eltrombopag,methylprednisolone,and platelet transfusion were given successively,but the PLT in the patients increased and decreased repeatedly,with the highest being 67×10^(9)/L,minimum 4×10^(9)/L.